Today: 12 June 2026
Browse Category

NYSE:LLY 17 January 2026 - 28 January 2026

Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week

Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week

Pfizer shares fell 1.8% to $26.02 after U.S. Medicare included Xeljanz in its upcoming drug price negotiations, set to begin in 2026 with prices effective in 2028. The Centers for Medicare & Medicaid Services named 15 drugs for talks, and companies must decide by February 28 whether to participate. Investors are awaiting Pfizer’s February 3 earnings for updates on pricing risks.
28 January 2026
······
Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal

Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal

Eli Lilly shares fell 2.4% to $1,015.05 Wednesday after the company announced a gene-editing deal with Seamless Therapeutics worth up to $1.12 billion. The U.S. government included Lilly’s Trulicity in the next round of Medicare drug-price negotiations, raising pricing concerns. Obesity drug rivals increased ad spending, intensifying competition.
28 January 2026
···
Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly shares closed down 2.3% at $1,039.51 Tuesday, then rose 0.3% after hours. U.S. Medicare officials named Lilly’s Trulicity among 15 drugs for 2028 price negotiations. The stock has dropped three straight sessions and now trades about 8% below its Jan. 8 peak. Investors await Lilly’s Feb. 4 earnings for updates on diabetes and obesity drug trends.
28 January 2026
·······
Eli Lilly stock slips in late morning trade as investors size up earnings and the obesity-pill race

Eli Lilly stock slips in late morning trade as investors size up earnings and the obesity-pill race

Eli Lilly shares slipped 0.1% to $1,062.87 in late morning trading Monday, extending last week’s decline. Investors are focused on the Feb. 4 earnings release and updates on obesity drug launches amid rising competition from Novo Nordisk. Early U.S. sales of Novo’s oral Wegovy and anticipation for Lilly’s orforglipron pill are drawing analyst attention. Legal and pricing pressures add uncertainty as both firms battle for market share.
26 January 2026
···
Healthcare stocks brace for a key week: XLV slips as Wegovy pill data and UnitedHealth earnings loom

Healthcare stocks brace for a key week: XLV slips as Wegovy pill data and UnitedHealth earnings loom

The Health Care Select Sector SPDR Fund (XLV) fell 0.5% to $157.48 Friday, with Eli Lilly down 2.1%. Johnson & Johnson and UnitedHealth posted small gains. Traders are watching obesity-drug demand and a crowded earnings calendar next week. The FDA linked ByHeart’s recalled infant formula to a multi-state botulism outbreak.
25 January 2026
·····
Eli Lilly stock slips as obesity-drug headlines pile up ahead of next week

Eli Lilly stock slips as obesity-drug headlines pile up ahead of next week

Eli Lilly shares fell 2.1% to $1,064.29 Friday after analysts reported Novo Nordisk’s new Wegovy pill logged 18,410 U.S. prescriptions in its first full week. Lilly’s Q4 results are due Feb. 4. India approved local firms to make generic semaglutide ahead of its 2026 patent expiry. New data showed many patients did not quickly regain weight after stopping GLP-1 drugs.
24 January 2026
···
Eli Lilly stock slips as Novo’s Wegovy pill racks up 18,000+ scripts; earnings next

Eli Lilly stock slips as Novo’s Wegovy pill racks up 18,000+ scripts; earnings next

Eli Lilly shares fell 1.1% to $1,075.78 after Novo Nordisk’s new Wegovy pill logged over 18,000 U.S. prescriptions in its first full week. Investors are watching ahead of Lilly’s Feb. 4 earnings and an expected FDA decision on its own oral obesity drug by April. Several Lilly directors recently received stock units through a deferral plan.
23 January 2026
····
Eli Lilly stock rises after hours as fresh GLP-1 stop data revives a big question ahead of earnings

Eli Lilly stock rises after hours as fresh GLP-1 stop data revives a big question ahead of earnings

Eli Lilly shares rose 0.8% after hours Thursday to $1,087.38. A Reuters report cited nference data showing 36% of patients who stopped Lilly’s weight-loss drug tirzepatide kept weight off after six months, while 28% regained weight. Lilly director Juan R. Luciano acquired 15.286 shares via a deferral plan, per SEC filing. The company reports Q4 earnings February 4.
23 January 2026
···
Eli Lilly stock rises as FDA gives ‘Breakthrough’ tag to ovarian cancer drug, earnings date set

Eli Lilly stock rises as FDA gives ‘Breakthrough’ tag to ovarian cancer drug, earnings date set

Eli Lilly shares rose 3.6% to $1,078.52 Wednesday after the FDA granted Breakthrough Therapy designation to its ovarian cancer drug candidate, sofetabart mipitecan. The company will report fourth-quarter earnings on February 4. Director Juan R. Luciano disclosed acquiring about 15 shares through deferred board compensation.
21 January 2026
···
Eli Lilly stock ticks up after FDA “breakthrough” tag for ovarian cancer drug

Eli Lilly stock ticks up after FDA “breakthrough” tag for ovarian cancer drug

Eli Lilly shares closed up 0.3% at $1,041.29 Tuesday and rose slightly after hours after the FDA granted Breakthrough Therapy status to its ovarian cancer drug candidate, sofetabart mipitecan. The designation targets adults with platinum-resistant ovarian cancer. Analyst Seamus Fernandez maintained a buy rating but trimmed his price target. Abivax’s CEO denied rumors of takeover talks with Lilly.
21 January 2026
·
Eli Lilly stock price edges higher after FDA breakthrough nod for ovarian cancer drug

Eli Lilly stock price edges higher after FDA breakthrough nod for ovarian cancer drug

Eli Lilly shares rose about 0.2% Tuesday after the FDA granted Breakthrough Therapy designation to its experimental ovarian cancer drug, sofetabart mipitecan. The stock traded near $1,040 as the broader market fell 1%. The designation covers patients with platinum-resistant disease who have tried other therapies. Bernstein maintained its Outperform rating and $1,300 price target.
20 January 2026
··
Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade

Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade

Eli Lilly shares rose 0.5% to $1,038.40 Friday, ahead of a holiday-shortened week. Traders are watching early U.S. prescription numbers for Novo Nordisk’s new oral Wegovy, which logged 3,071 scripts in its debut, just below Lilly’s Zepbound. U.S. markets reopen Tuesday, with investors eyeing fresh demand signals and pricing risks. About 3.8 million Lilly shares traded Friday.
19 January 2026
···
Eli Lilly stock price: What to watch after Friday’s close as FDA review scrutiny and Novo’s pill data hit

Eli Lilly stock price: What to watch after Friday’s close as FDA review scrutiny and Novo’s pill data hit

Eli Lilly shares closed Friday at $1,038.40, up 0.5% after trading between $1,019 and $1,049.83. Investors are watching for FDA decisions on Lilly’s obesity pill and tracking early prescription data as Novo Nordisk’s Wegovy pill posts strong initial sales. U.S. markets will be closed Monday, reopening Tuesday. Lilly’s next earnings call is scheduled for February 4.
18 January 2026
··
Eli Lilly stock price in focus as FDA slips obesity pill deadline — what to watch in LLY next week

Eli Lilly stock price in focus as FDA slips obesity pill deadline — what to watch in LLY next week

Eli Lilly shares rose 0.5% to $1,038.40 Friday as the FDA set April 10 as the new target date for a decision on its experimental weight-loss pill. The agency delayed review timelines for several drugs, including Lilly’s, under its fast-track program. Novo Nordisk’s new Wegovy pill saw about 3,071 U.S. prescriptions in its first four days, according to IQVIA data.
17 January 2026
··
1 2 3 4 5 6 … 13

Stock Market Today

  • Oracle Shares Fall on $20 Billion Fundraising; Navan, Anterix, Driven Brands Beat Estimates
    June 12, 2026, 7:12 AM EDT. Oracle Corp (ORCL) shares dropped 8.5% after announcing a $20 billion equity and debt raise to fund AI development, alongside reporting annual negative free cash flow. Meanwhile, Navan Inc (NAVN) surged 8.4% after beating first-quarter fiscal 2027 adjusted earnings estimates with $0.08 per share compared to a loss of $0.01. Anterix Inc (ATEX) shares jumped 25.7% after posting a narrower adjusted loss than expected for Q4 fiscal 2026. Driven Brands Holdings Inc (DRVN) rose 2.1% following better-than-expected adjusted earnings per share of $0.30. These moves highlight shifting investor focus amid the ongoing AI expansion beyond major infrastructure players.

Latest articles

OpenAI and Anthropic IPO talk grows as SpaceX sticks to $75 billion mark

OpenAI and Anthropic IPO talk grows as SpaceX sticks to $75 billion mark

12 June 2026
SpaceX’s $75 billion IPO sets a $1.77 trillion valuation benchmark as it prepares to begin Nasdaq trading Friday, more than doubling Saudi Aramco’s 2019 record and making SpaceX one of the most valuable U.S.-listed companies, with the first sessions expected to influence how investors and bankers approach upcoming OpenAI and Anthropic IPOs.
Go toTop